Olema Pharmaceuticals (OLMA) Income from Continuing Operations (2020 - 2026)
Olema Pharmaceuticals (OLMA) posted quarterly Income from Continuing Operations of 145101000.0 for Q1 2026, down 358.18% year-over-year from 56201503.97 in Q1 2025, and down 212.88% quarter-over-quarter from 46376000.0 in Q4 2025.
Olema Pharmaceuticals (OLMA) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has reported Income from Continuing Operations for 7 consecutive years, with 145101000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 358.18% year-over-year to 145101000.0; the TTM figure through Mar 2026 stood at 279772000.0 (down 32.03% YoY), while the FY2025 annual figure was 398134000.0, down 190.41% from the prior year.
- Income from Continuing Operations slipped to 145101000.0 in Q1 2026 per OLMA's latest filing, from 46376000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 25797000.0 in Q3 2022 and bottomed at 145101000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 50773117.65 across 5 years, with a median of 42541000.0 in 2025.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations soared 78.22% — and 2026, when it tumbled 358.18%.
- Olema Pharmaceuticals' Income from Continuing Operations stood at 26569000.0 in 2022, then fell by 2.1% to 27128000.0 in 2023, then slipped by 24.52% to 33780000.0 in 2024, then tumbled by 37.29% to 46376000.0 in 2025, then plunged by 212.88% to 145101000.0 in 2026.
- Business Quant data shows OLMA's Income from Continuing Operations at 145101000.0 in Q1 2026, 46376000.0 in Q4 2025, and 42541000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Olema Pharmaceuticals | 930.10 Mn | 930.10 Mn | - | -131.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -131.35 Mn |
| Mar 31, 2026 | -145.10 Mn |
| Dec 31, 2025 | -46.38 Mn |
| Sep 30, 2025 | -42.54 Mn |
| Jun 30, 2025 | -45.75 Mn |
| Mar 31, 2025 | -31.67 Mn |
| Dec 31, 2024 | -33.78 Mn |
| Sep 30, 2024 | -78.93 Mn |
| Jun 30, 2024 | -67.53 Mn |
| Mar 31, 2024 | -71.72 Mn |
| Dec 31, 2023 | -27.13 Mn |
| Sep 30, 2023 | -75.36 Mn |
| Jun 30, 2023 | -51.62 Mn |
| Mar 31, 2023 | -30.33 Mn |
| Dec 31, 2022 | -26.57 Mn |
| Sep 30, 2022 | -25.80 Mn |
| Jun 30, 2022 | -36.40 Mn |
| Mar 31, 2022 | -26.55 Mn |
| Dec 31, 2021 | -42.72 Mn |
| Sep 30, 2021 | -89.42 Mn |